Endpoint Health Launches with Mission to Bring Life-Saving Targeted Therapies to Patients with Critical Illnesses
Company emerges from stealth with $12 million in financing led by Mayfield to make targeted therapies a reality for the sickest patients in the hospital
Palo Alto, Calif. – July 13, 2020 –Endpoint Health launched today on a mission to bring life-saving targeted therapies to patients with critical illnesses including sepsis and acute respiratory distress syndrome (ARDS) — life-threatening conditions often caused by serious infections, including COVID-19. The first targeted therapeutics company focused on integrated solutions for critical illnesses, Endpoint Health’s mission is to combine novel and on-market therapeutics, companion diagnostics and artificial intelligence (AI) into an integrated platform designed to improve outcomes in critically ill patients.
The company has received $12 million in debt and equity financing from top-tier investors including Mayfield, Y Combinator, AME Cloud Ventures, and Wireframe Ventures. Endpoint Health is led by an experienced executive team including the co-founders of GeneWEAVE, an infection detection and therapy guidance company that was acquired by Roche in a 2015 deal valued at $425 million. The company is collaborating with more than 40 top U.S. and international hospitals with a focus on bringing targeted therapies to critically ill patients.
“Critical illnesses make up half of U.S. hospital mortality and over $100 billion of our annual healthcare spend. Sepsis alone is associated with as many global deaths as cancer each year, and yet patients with these life-threatening illnesses still have few treatment options,” said Jason Springs, co-founder and CEO of Endpoint Health. “The COVID-19 pandemic, which placed unprecedented numbers of patients in the ICU, has drawn the world’s attention to the desperate need for advances in this field. We need a new approach to how we understand these illnesses, and how we develop and deliver treatments.”
Endpoint Health’s unique approach combines molecular and digital patient data with AI to create comprehensive therapeutic models—tools that identify distinct patient subgroups and treatment patterns in order to highlight unmet therapeutic needs. These models are used to identify late-stage and on-market therapies, often created for other indications, that Endpoint can develop into targeted therapies, which will include the required tests and software to guide their use. The company’s vision is to empower clinicians with an array of approved therapeutic solutions that can be targeted to each unique patient to improve clinical outcomes.
“We were honored to partner with Jason, Diego, Leo, and Jeff from the inception of Endpoint Health as they started on this journey to save thousands of lives,” said Ursheet Parikh, leader of the Healthcare & Genomics investment practice for Mayfield. “The founders aspire to build a new category of healthcare company that can address the massive medical needs of critically ill patients which remain unmet by the established healthcare industry.”
“One of the biggest ongoing challenges for critical care physicians is treating life-threatening illnesses like sepsis and ARDS,” said Dr. Hector Wong, Director of Critical Care Medicine at Cincinnati Children’s Hospital. “These aren’t single diseases, they’re heterogeneous syndromes, and we can see this in clinical practice—some patients respond to a specific therapy, while others with similar clinical presentation don’t. We need to target therapies to the right patient at the right time to gain real improvement. We’ve seen this approach transform oncology over the last few decades, and I’m excited by the potential for Endpoint’s approach to do the same in critical care.”
“What I like about our collaboration with Endpoint Health is that they approach solving patient problems the way clinicians do: you have to untangle their complex nature and personalize all of the patient’s care. Critically ill patients require multiple therapies that may range from routine care such as fluids, to novel therapies,” said Dr. Todd Rice, Director of the Medical Intensive Care Unit at Vanderbilt University Medical Center in Nashville, Tenn. “At the end of the day, if your goal is to improve the outcome of a patient, you have to care about targeting both routine and novel therapies.”
About Endpoint Health
Endpoint Health combines therapeutics, companion diagnostics, and artificial intelligence (AI) into an integrated platform designed to improve outcomes of patients with critical illnesses like sepsis, acute respiratory distress syndrome (ARDS) and COVID-19. The company is based in Palo Alto, Calif., with offices in Detroit and Chicago, and is backed by top-tier investors including Mayfield, Y Combinator, AME Cloud Ventures, and Wireframe Ventures. For more information visit www.endpoint.health.